Google's C2S-Scale 27B model generates a new cancer-immunotherapy hypothesis confirmed in living cells
C2S-Scale 27B, a Gemma-based single-cell model, simulated over 4,000 drugs in two immune contexts. It predicted that the CK2 inhibitor silmitasertib boosts tumour antigen presentation only with low-dose interferon present. In living cells the combination raised MHC-I antigen presentation by ~50%. The link had not been reported before.
Key facts
- Virtual screen of >4,000 drugs in 'immune-context-positive' vs '-neutral' settings
- Silmitasertib (CX-4945) + low-dose interferon: ~50% increase in antigen presentation in vitro
- In vitro only; no animal or clinical data; preprint
Science result
- Field
- medicine / cancer immunology
- Problem
- Making 'cold' tumours visible to the immune system
- Result
- Novel, context-dependent drug synergy predicted by an LLM-style single-cell model and confirmed in cell experiments.
- AI system
- C2S-Scale 27B (Gemma)
- Human role
- AI-generated hypothesis; human lab validation
- Verification
- Lab-validated in vitro; preprint
- Status
- confirmed
What happened
Researchers asked the model which drugs would amplify immune signals only in an immune-active context. Its top novel prediction held up in lab tests.
Why it matters
It is evidence that scaling biological foundation models can yield testable, novel hypotheses, though only in vitro so far.
Changelog
- 2026-09-29: created
Related events
- Google's AI co-scientist independently reproduces an unpublished superbug discovery in 48 hours ★★★★
Sources (2)
- officialGoogle: How a Gemma model helped discover a new potential cancer therapy pathway
- pressDDW: Google AI model reveals new way to improve immunotherapy
id: 2025-10-15-c2s-scale-gemma-cancer-hypothesis · updated 2026-09-29 · open in the interactive timeline